Mass tort and class action settlements totaled over $40 billion for the third year in a row. While this number is staggering, unlocking its history provides key considerations to dial back this billion-dollar settlement trend. Mass tort litigation has been a part of the American legal system for decades. Settlements have been the end of a long road of bellwether trials, ultimately resolving the litigation.

Probiotics are skyrocketing in popularity. While they are classified as dietary supplements, probiotics are often being marketed and used to treat symptoms and illnesses despite not having FDA approval, which can lead to safety concerns for consumers.

Beginning in the 1960s, medical facilities, blood banks, and other public providers of blood products began seeing limited statutory protections arise in most states through what has become known as “blood shield laws.”

Psychedelic drugs have long fascinated humanity, from use in ancient rituals to potential therapeutic benefits. Among these, psilocybin, the active compound in "magic mushrooms," stands out for its historical significance and promising future. This article delves into the legal status, clinical trials, history, and future of psychedelic drugs, with a particular focus on psilocybin.

Not so long ago, genetic testing was aspirational, a process more common to science fiction than accepted medical research. Over the past several decades, however, genetic testing and gene therapy have become mainstream. 

Orthopedic and oral/maxillofacial implants currently represent a combined $2.8 billion market, a figure expected to experience significant and continued growth. Although traditional permanent implants have proven clinically efficacious, they are also associated with several drawbacks, including secondary surgeries, infection, and rejection.

Recently, Magna Legal Services, a company that provides legal support and consulting services, interviewed Berkley Life Sciences Cynthia "Cindy" Khin, Life Sciences Casualty Resolution Director. The following is their conversation about Cindy’s career path and the importance of mock trials.

In a previous post, we discussed the FDA’s July 2024 Draft Guidance entitled "Addressing Misinformation About Medical Devices and Prescription Drugs: Questions and Answers" (the "Draft Guidance"). The Draft Guidance suggests a purportedly voluntary pathway for drug and device sponsors, manufacturers, distributors, and other stakeholders legally responsible for the labeling of approved/cleared medical products ("firms") to respond to internet-based posts and comments in a manner consistent with existing product labeling and advertising laws.